Junevity

Executive Summary

Junevity is a preclinical-stage biotechnology company pioneering siRNA-based cell reprogramming to extend human healthspan and reverse age-related diseases. Founded in 2021 and headquartered in San Francisco, the company leverages its proprietary RESET platform to identify and target key transcription factors that drive transcriptional dysregulation in aging. Its initial therapeutic focus is on metabolic diseases and neurodegeneration, with the aim of addressing fundamental aging processes rather than single disease pathways. The RESET platform enables the design of small interfering RNAs (siRNAs) that silence specific transcription factors, thereby reprogramming cellular gene expression to a more youthful state. This approach has the potential to treat multiple age-related conditions simultaneously, representing a paradigm shift in the field of geroscience. However, the company is at an early stage with no disclosed funding rounds or clinical data, and its technology is yet to be validated in humans. The success of Junevity hinges on demonstrating efficacy and safety in preclinical models, securing financing, and advancing toward first-in-human studies. The aging biology field is highly competitive, but the company's unique siRNA-based reprogramming approach offers a differentiated strategy with broad applicability. Key risks include technical challenges in siRNA delivery to target tissues and the complexity of reversing global transcriptional changes without unintended effects.

Upcoming Catalysts (preview)

• Q3 2026Preclinical proof-of-concept data for lead metabolic disease program60% success
• Q3 2026Series A financing round70% success
• Q4 2026Nomination of development candidate for neurodegenerative indication50% success